There is no connection between the HPV vaccine and an increased risk of blood clots, according to a new study. The new post-approval study followed 1.6 million Danish women and has indicated that there is no heightened risk of developing a blood clot within 42 days after receiving the vaccination.
The study results are published in the July 9 edition of JAMA.
The authors said in a statement, “Safety concerns can compromise immunization programs to the detriment of public health, and timely evaluations of such concerns are essential.”
Two prior reports from the Centers for Disease Control and Prevention in the U.S. noted a possible link between this vaccination and rare instances of blood clots, helping to drive this study.
The study consisted of Danish women between the ages of 10 and 44, between October 2006 and July 2013. Included in the study were 500,345, or 31 percent, who were given the quadrivalent HPV vaccination. There were 4,375 incident cases of venous thromboembolism, or VTE. Of the total participants, 889 women, or 20 percent, received vaccinations within the study period.
According to the U.S. Food and Drug Administration, HPV, or human papillomavirus, is a sexually transmitted disease that is passed on through genital contact as well as by skin-to-skin contact.